Abivax (AAVXF) Beginning Cash Balance (2024)
Abivax (AAVXF) posted Beginning Cash Balance of $271.3 million for Q2 2024.
Powered by 
Analysis
Abivax (AAVXF) Beginning Cash Balance (2024) Analysis & Trends
Abivax has reported Beginning Cash Balance for 1 years, with the latest figure at $271.3 million in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 210.97 Bn | 196.98 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.98 Bn | 177.80 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.09 Bn | 124.24 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.57 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.71 Bn | 56.53 Bn | 1.37 Bn |
| 6 | Moderna | 54.60 Bn | 49.46 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.02 Bn | 30.71 Bn | 992.69 Mn |
| 8 | Biogen | 31.25 Bn | 29.97 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.76 Bn | 29.76 Bn | 1.16 Mn |
| 10 | Abivax | 10.92 Bn | 10.92 Bn | - |